Lozano-Cuenca Jair, Muñoz-Islas Enriqueta, González-Hernández Abimael, Centurión David, Cobos-Puc Luis E, Sánchez-López Araceli, Pertz Heinz H, Villalón Carlos M
Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de los Tenorios 235, Col. Granjas-Coapa, Deleg. Tlalpan, C.P. 14330 México D.F., México.
Eur J Pharmacol. 2009 Jun 10;612(1-3):80-6. doi: 10.1016/j.ejphar.2009.03.072. Epub 2009 Apr 6.
The present study set out to analyse the pharmacological profile of the inhibitory responses induced by the antimigraine agents dihydroergotamine (DHE) and methysergide on the tachycardic responses to preganglionic sympathetic stimulation in pithed rats. For this purpose, 132 male Wistar normotensive rats were pithed and prepared to: (i) selectively stimulate the preganglionic (C(7)-T(1)) cardiac sympathetic outflow; or (ii) receive intravenous (i.v.) bolus injections of exogenous noradrenaline. Electrical sympathetic stimulation or exogenous noradrenaline produced, respectively, frequency-dependent and dose-dependent tachycardic responses. Moreover, i.v. continuous infusions of DHE (1.8, 3.1 and 5.6 microg/kg x min) or methysergide (100, 300 and 1000 microg/kg x min) dose-dependently inhibited the tachycardic responses to sympathetic stimulation, but not those to exogenous noradrenaline. Using physiological saline or antagonists (given as i.v. bolus injections), the cardiac sympatho-inhibition induced by either DHE (3.1 microg/kg x min) or methysergide (300 microg/kg x min) was: (1) unaffected by saline (1 ml/kg); (2) partially blocked by the antagonists rauwolscine (300 microg/kg; alpha(2)) or N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1,-biphenyl]-4-carboxamide hydrochloride monohydrate (GR127935, 300 microg/kg; 5-HT(1B/1D)); and (3) completely antagonised by the combination rauwolscine plus GR127935. These antagonists, at doses high enough to completely block their respective receptors, failed to modify the sympathetically-induced tachycardic responses per se. The above results, taken together, suggest that the cardiac sympatho-inhibition induced by DHE (3.1 microg/kg x min) and methysergide (300 microg/kg x min) may be mainly mediated by stimulation of both alpha(2)-adrenoceptors and 5-HT(1B/1D) receptors.
本研究旨在分析抗偏头痛药物双氢麦角胺(DHE)和甲基麦角新碱对脊髓麻醉大鼠节前交感神经刺激所致心动过速反应的抑制作用的药理学特征。为此,选取132只雄性Wistar正常血压大鼠进行脊髓麻醉并准备用于:(i)选择性刺激节前(C7 - T1)心脏交感神经传出;或(ii)接受静脉推注外源性去甲肾上腺素。电交感神经刺激或外源性去甲肾上腺素分别产生频率依赖性和剂量依赖性心动过速反应。此外,静脉持续输注DHE(1.8、3.1和5.6微克/千克·分钟)或甲基麦角新碱(100、300和1000微克/千克·分钟)剂量依赖性地抑制对交感神经刺激的心动过速反应,但不抑制对外源性去甲肾上腺素的反应。使用生理盐水或拮抗剂(静脉推注),由DHE(3.1微克/千克·分钟)或甲基麦角新碱(300微克/千克·分钟)诱导的心脏交感神经抑制作用:(1)不受生理盐水(1毫升/千克)影响;(2)被拮抗剂萝芙素(300微克/千克;α2)或N - [4 - 甲氧基 - 3 - (4 - 甲基 - 1 - 哌嗪基)苯基] - 2'-甲基 - 4'-(5 - 甲基 - 1,2,4 - 恶二唑 - 3 - 基)[1,1 - 联苯] - 4 - 羧酰胺盐酸盐一水合物(GR127935,300微克/千克;5 - HT1B/1D)部分阻断;(3)被萝芙素加GR127935的组合完全拮抗。这些拮抗剂在足以完全阻断其各自受体的剂量下,本身未能改变交感神经诱导的心动过速反应。综上所述,上述结果表明,DHE(3.1微克/千克·分钟)和甲基麦角新碱(300微克/千克·分钟)诱导的心脏交感神经抑制作用可能主要由α2 - 肾上腺素能受体和5 - HT1B/1D受体的刺激介导。